At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Tabalumab +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of Tabalumab (LY2127399) in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed or Refractory Multiple Myeloma
In Brief
A Phase 1 clinical trial evaluating Tabalumab, Bortezomib IV, and 2 other interventions for Multiple Myeloma. Completed, enrolled 16 participants across 5 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and effect on the body of Tabalumab (LY2127399) in combination with bortezomib and dexamethasone in Japanese participants with relapsed or refractory multiple myeloma (MM).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 2012
Enrollment StartJul 2012
Primary CompletionFeb 2015
Study CompletionAug 2015
TodayJul 2026
First PostedMar 16, 2012
Enrollment StartJul 1, 2012
Primary CompletionFeb 1, 2015
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 14.3 years ago
Interventions
Tabalumabbiological
Administered IV
Bortezomib IVdrug
Administered IV
Bortezomib SCdrug
Administered SC
Dexamethasonedrug
Administered orally